Global Hib Vaccine

Hib Vaccine Comprehensive Study by Type (Type 1-HIB Vaccine, Type 2- DTaP-IPV), Form (Liquid Monovalent HIB, Liquid Combination HIB, Lyophilized Monovalent HIB, Lyophilized Combination HIB), Age Group (Below 12-15 months ( Infants), 15 months -5 years, 5 years and Above), Infections (Meningitis (Inflammation Of The Lining Of The Brain And Spinal Cord), Bacteremia (Infection Of The Bloodstream), Pneumonia (Lung Infection), Epiglottitis (Throat Infection)), End User (Hospital, Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others) Players and Region - Global Market Outlook to 2026

Hib Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Hib Vaccine?
Influenzae type B is a common organism worldwide it is found in most healthy individuals in the general population. Little kids can get the bacteria from individuals who don't know that they are carriers. When the bacteria spread to the lungs and bloodstream, serious illnesses, including pneumonia and meningitis, can result. Another serious disease stemming from this pathogen is epiglottitis, an infection of the epiglottis that causes swelling of the airways and potential death. The Hib vaccine is a kind of treatment that helps protect children from contracting infections due to Haemophilus influenzae type B (Hib), a bacterium that is capable of causing little kids can get the bacteria from individuals who don't know that they are carriers. The first dose starts at about two months of age, and the last is usually scheduled at a 12- or 15-month check-up. Youngsters older than five years needn't bother with vaccination, except if the kid or adolescent has a genuine medical issue that brings down immunity, for example, HIV contamination, sickle cell illness, or is being treated for cancer. According to the research, Nearly 1,000 people in the United States died every year from Hib disease. As of the mid-2000s, the infection has to a great extent vanished because of these vaccinations. In developing nations, nonetheless, Hib disease is a significant reason for genuine infection and demise in small kids thus the demand for hib vaccine is booming.

The market study is broken down by Type (Type 1-HIB Vaccine and Type 2- DTaP-IPV) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA Research estimates that Players from United States and United Kingdom will contribute to the maximum growth of Global Hib Vaccine market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca (United Kingdom), SINOPHARM (China), Weldon Biotech, Inc. (India), McKesson Corporation (United States), Novartis (Switzerland), Merck Sharp & Dohme Corp (United States), Sanofi Pasteur (Canada), GlaxoSmithKline (United Kingdom), Takeda Pharmaceuticals Company Ltd.(Japan) and Walvax Biotechnology Co. Ltd. (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Lanzhou Institute of Biological Products Co., Ltd(China), Bharat Biotech(India), Serum Institute of India Pvt. Ltd (India) and Seqirus (United Kingdom).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Hib Vaccine market by Type, Application and Region.

On the basis of geography, the market of Hib Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Form, the sub-segment i.e. Liquid Monovalent HIB will boost the Hib Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age Group, the sub-segment i.e. Below 12-15 months ( Infants) will boost the Hib Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Infections, the sub-segment i.e. Meningitis (Inflammation Of The Lining Of The Brain And Spinal Cord) will boost the Hib Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Hib Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.




Market Trend
  • Government agencies in collaboration with international healthcare

Market Drivers
  • The rapid development of efficient Hib Vaccine
  • Increasing Hib Vaccine prevalence and the high sales of vaccines
  • The initiatives are taken by governments and private organizations

Opportunities
  • The increasing prevalence of chronic diseases and the rising death rate due to the Hib Vaccine are propelling the government to promote vaccination across the globe thus booming the growth opportunities
  • Emerging demand from the developing countries

Restraints
  • The adverse effect of the Hib Vaccine

Challenges
  • High prices of Vaccines


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Hib Vaccine Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Type 1-HIB Vaccine
  • Type 2- DTaP-IPV
By Form
  • Liquid Monovalent HIB
  • Liquid Combination HIB
  • Lyophilized Monovalent HIB
  • Lyophilized Combination HIB

By Age Group
  • Below 12-15 months ( Infants)
  • 15 months -5 years
  • 5 years and Above

By Infections
  • Meningitis (Inflammation Of The Lining Of The Brain And Spinal Cord)
  • Bacteremia (Infection Of The Bloodstream)
  • Pneumonia (Lung Infection)
  • Epiglottitis (Throat Infection)

By End User
  • Hospital
  • Research & Academic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The rapid development of efficient Hib Vaccine
      • 3.2.2. Increasing Hib Vaccine prevalence and the high sales of vaccines
      • 3.2.3. The initiatives are taken by governments and private organizations
    • 3.3. Market Challenges
      • 3.3.1. High prices of Vaccines
    • 3.4. Market Trends
      • 3.4.1. Government agencies in collaboration with international healthcare
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hib Vaccine, by Type, Form, Age Group, Infections, End User and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hib Vaccine (Value)
      • 5.2.1. Global Hib Vaccine by: Type (Value)
        • 5.2.1.1. Type 1-HIB Vaccine
        • 5.2.1.2. Type 2- DTaP-IPV
      • 5.2.2. Global Hib Vaccine by: Form (Value)
        • 5.2.2.1. Liquid Monovalent HIB
        • 5.2.2.2. Liquid Combination HIB
        • 5.2.2.3. Lyophilized Monovalent HIB
        • 5.2.2.4. Lyophilized Combination HIB
      • 5.2.3. Global Hib Vaccine by: Age Group (Value)
        • 5.2.3.1. Below 12-15 months ( Infants)
        • 5.2.3.2. 15 months -5 years
        • 5.2.3.3. 5 years and Above
      • 5.2.4. Global Hib Vaccine by: Infections (Value)
        • 5.2.4.1. Meningitis (Inflammation Of The Lining Of The Brain And Spinal Cord)
        • 5.2.4.2. Bacteremia (Infection Of The Bloodstream)
        • 5.2.4.3. Pneumonia (Lung Infection)
        • 5.2.4.4. Epiglottitis (Throat Infection)
      • 5.2.5. Global Hib Vaccine by: End User (Value)
        • 5.2.5.1. Hospital
        • 5.2.5.2. Research & Academic Laboratories
        • 5.2.5.3. Pharmaceutical & Biotechnology Companies
        • 5.2.5.4. Others
      • 5.2.6. Global Hib Vaccine Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Hib Vaccine (Volume)
      • 5.3.1. Global Hib Vaccine by: Type (Volume)
        • 5.3.1.1. Type 1-HIB Vaccine
        • 5.3.1.2. Type 2- DTaP-IPV
      • 5.3.2. Global Hib Vaccine by: Form (Volume)
        • 5.3.2.1. Liquid Monovalent HIB
        • 5.3.2.2. Liquid Combination HIB
        • 5.3.2.3. Lyophilized Monovalent HIB
        • 5.3.2.4. Lyophilized Combination HIB
      • 5.3.3. Global Hib Vaccine by: Age Group (Volume)
        • 5.3.3.1. Below 12-15 months ( Infants)
        • 5.3.3.2. 15 months -5 years
        • 5.3.3.3. 5 years and Above
      • 5.3.4. Global Hib Vaccine by: Infections (Volume)
        • 5.3.4.1. Meningitis (Inflammation Of The Lining Of The Brain And Spinal Cord)
        • 5.3.4.2. Bacteremia (Infection Of The Bloodstream)
        • 5.3.4.3. Pneumonia (Lung Infection)
        • 5.3.4.4. Epiglottitis (Throat Infection)
      • 5.3.5. Global Hib Vaccine by: End User (Volume)
        • 5.3.5.1. Hospital
        • 5.3.5.2. Research & Academic Laboratories
        • 5.3.5.3. Pharmaceutical & Biotechnology Companies
        • 5.3.5.4. Others
      • 5.3.6. Global Hib Vaccine Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Hib Vaccine (Price)
      • 5.4.1. Global Hib Vaccine by: Type (Price)
  • 6. Hib Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. SINOPHARM (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Weldon Biotech, Inc. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. McKesson Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck Sharp & Dohme Corp (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi Pasteur (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Takeda Pharmaceuticals Company Ltd.(Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Walvax Biotechnology Co. Ltd. (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hib Vaccine Sale, by Type, Form, Age Group, Infections, End User and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Hib Vaccine (Value)
      • 7.2.1. Global Hib Vaccine by: Type (Value)
        • 7.2.1.1. Type 1-HIB Vaccine
        • 7.2.1.2. Type 2- DTaP-IPV
      • 7.2.2. Global Hib Vaccine by: Form (Value)
        • 7.2.2.1. Liquid Monovalent HIB
        • 7.2.2.2. Liquid Combination HIB
        • 7.2.2.3. Lyophilized Monovalent HIB
        • 7.2.2.4. Lyophilized Combination HIB
      • 7.2.3. Global Hib Vaccine by: Age Group (Value)
        • 7.2.3.1. Below 12-15 months ( Infants)
        • 7.2.3.2. 15 months -5 years
        • 7.2.3.3. 5 years and Above
      • 7.2.4. Global Hib Vaccine by: Infections (Value)
        • 7.2.4.1. Meningitis (Inflammation Of The Lining Of The Brain And Spinal Cord)
        • 7.2.4.2. Bacteremia (Infection Of The Bloodstream)
        • 7.2.4.3. Pneumonia (Lung Infection)
        • 7.2.4.4. Epiglottitis (Throat Infection)
      • 7.2.5. Global Hib Vaccine by: End User (Value)
        • 7.2.5.1. Hospital
        • 7.2.5.2. Research & Academic Laboratories
        • 7.2.5.3. Pharmaceutical & Biotechnology Companies
        • 7.2.5.4. Others
      • 7.2.6. Global Hib Vaccine Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Hib Vaccine (Volume)
      • 7.3.1. Global Hib Vaccine by: Type (Volume)
        • 7.3.1.1. Type 1-HIB Vaccine
        • 7.3.1.2. Type 2- DTaP-IPV
      • 7.3.2. Global Hib Vaccine by: Form (Volume)
        • 7.3.2.1. Liquid Monovalent HIB
        • 7.3.2.2. Liquid Combination HIB
        • 7.3.2.3. Lyophilized Monovalent HIB
        • 7.3.2.4. Lyophilized Combination HIB
      • 7.3.3. Global Hib Vaccine by: Age Group (Volume)
        • 7.3.3.1. Below 12-15 months ( Infants)
        • 7.3.3.2. 15 months -5 years
        • 7.3.3.3. 5 years and Above
      • 7.3.4. Global Hib Vaccine by: Infections (Volume)
        • 7.3.4.1. Meningitis (Inflammation Of The Lining Of The Brain And Spinal Cord)
        • 7.3.4.2. Bacteremia (Infection Of The Bloodstream)
        • 7.3.4.3. Pneumonia (Lung Infection)
        • 7.3.4.4. Epiglottitis (Throat Infection)
      • 7.3.5. Global Hib Vaccine by: End User (Volume)
        • 7.3.5.1. Hospital
        • 7.3.5.2. Research & Academic Laboratories
        • 7.3.5.3. Pharmaceutical & Biotechnology Companies
        • 7.3.5.4. Others
      • 7.3.6. Global Hib Vaccine Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Hib Vaccine (Price)
      • 7.4.1. Global Hib Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hib Vaccine: by Type(USD Million)
  • Table 2. Hib Vaccine Type 1-HIB Vaccine , by Region USD Million (2015-2020)
  • Table 3. Hib Vaccine Type 2- DTaP-IPV , by Region USD Million (2015-2020)
  • Table 4. Hib Vaccine: by Form(USD Million)
  • Table 5. Hib Vaccine Liquid Monovalent HIB , by Region USD Million (2015-2020)
  • Table 6. Hib Vaccine Liquid Combination HIB , by Region USD Million (2015-2020)
  • Table 7. Hib Vaccine Lyophilized Monovalent HIB , by Region USD Million (2015-2020)
  • Table 8. Hib Vaccine Lyophilized Combination HIB , by Region USD Million (2015-2020)
  • Table 9. Hib Vaccine: by Age Group(USD Million)
  • Table 10. Hib Vaccine Below 12-15 months ( Infants) , by Region USD Million (2015-2020)
  • Table 11. Hib Vaccine 15 months -5 years , by Region USD Million (2015-2020)
  • Table 12. Hib Vaccine 5 years and Above , by Region USD Million (2015-2020)
  • Table 13. Hib Vaccine: by Infections(USD Million)
  • Table 14. Hib Vaccine Meningitis (Inflammation Of The Lining Of The Brain And Spinal Cord) , by Region USD Million (2015-2020)
  • Table 15. Hib Vaccine Bacteremia (Infection Of The Bloodstream) , by Region USD Million (2015-2020)
  • Table 16. Hib Vaccine Pneumonia (Lung Infection) , by Region USD Million (2015-2020)
  • Table 17. Hib Vaccine Epiglottitis (Throat Infection) , by Region USD Million (2015-2020)
  • Table 18. Hib Vaccine: by End User(USD Million)
  • Table 19. Hib Vaccine Hospital , by Region USD Million (2015-2020)
  • Table 20. Hib Vaccine Research & Academic Laboratories , by Region USD Million (2015-2020)
  • Table 21. Hib Vaccine Pharmaceutical & Biotechnology Companies , by Region USD Million (2015-2020)
  • Table 22. Hib Vaccine Others , by Region USD Million (2015-2020)
  • Table 23. South America Hib Vaccine, by Country USD Million (2015-2020)
  • Table 24. South America Hib Vaccine, by Type USD Million (2015-2020)
  • Table 25. South America Hib Vaccine, by Form USD Million (2015-2020)
  • Table 26. South America Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 27. South America Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 28. South America Hib Vaccine, by End User USD Million (2015-2020)
  • Table 29. Brazil Hib Vaccine, by Type USD Million (2015-2020)
  • Table 30. Brazil Hib Vaccine, by Form USD Million (2015-2020)
  • Table 31. Brazil Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 32. Brazil Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 33. Brazil Hib Vaccine, by End User USD Million (2015-2020)
  • Table 34. Argentina Hib Vaccine, by Type USD Million (2015-2020)
  • Table 35. Argentina Hib Vaccine, by Form USD Million (2015-2020)
  • Table 36. Argentina Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 37. Argentina Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 38. Argentina Hib Vaccine, by End User USD Million (2015-2020)
  • Table 39. Rest of South America Hib Vaccine, by Type USD Million (2015-2020)
  • Table 40. Rest of South America Hib Vaccine, by Form USD Million (2015-2020)
  • Table 41. Rest of South America Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 42. Rest of South America Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 43. Rest of South America Hib Vaccine, by End User USD Million (2015-2020)
  • Table 44. Asia Pacific Hib Vaccine, by Country USD Million (2015-2020)
  • Table 45. Asia Pacific Hib Vaccine, by Type USD Million (2015-2020)
  • Table 46. Asia Pacific Hib Vaccine, by Form USD Million (2015-2020)
  • Table 47. Asia Pacific Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 48. Asia Pacific Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 49. Asia Pacific Hib Vaccine, by End User USD Million (2015-2020)
  • Table 50. China Hib Vaccine, by Type USD Million (2015-2020)
  • Table 51. China Hib Vaccine, by Form USD Million (2015-2020)
  • Table 52. China Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 53. China Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 54. China Hib Vaccine, by End User USD Million (2015-2020)
  • Table 55. Japan Hib Vaccine, by Type USD Million (2015-2020)
  • Table 56. Japan Hib Vaccine, by Form USD Million (2015-2020)
  • Table 57. Japan Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 58. Japan Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 59. Japan Hib Vaccine, by End User USD Million (2015-2020)
  • Table 60. India Hib Vaccine, by Type USD Million (2015-2020)
  • Table 61. India Hib Vaccine, by Form USD Million (2015-2020)
  • Table 62. India Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 63. India Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 64. India Hib Vaccine, by End User USD Million (2015-2020)
  • Table 65. South Korea Hib Vaccine, by Type USD Million (2015-2020)
  • Table 66. South Korea Hib Vaccine, by Form USD Million (2015-2020)
  • Table 67. South Korea Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 68. South Korea Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 69. South Korea Hib Vaccine, by End User USD Million (2015-2020)
  • Table 70. Taiwan Hib Vaccine, by Type USD Million (2015-2020)
  • Table 71. Taiwan Hib Vaccine, by Form USD Million (2015-2020)
  • Table 72. Taiwan Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 73. Taiwan Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 74. Taiwan Hib Vaccine, by End User USD Million (2015-2020)
  • Table 75. Australia Hib Vaccine, by Type USD Million (2015-2020)
  • Table 76. Australia Hib Vaccine, by Form USD Million (2015-2020)
  • Table 77. Australia Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 78. Australia Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 79. Australia Hib Vaccine, by End User USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Hib Vaccine, by Type USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Hib Vaccine, by Form USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Hib Vaccine, by End User USD Million (2015-2020)
  • Table 85. Europe Hib Vaccine, by Country USD Million (2015-2020)
  • Table 86. Europe Hib Vaccine, by Type USD Million (2015-2020)
  • Table 87. Europe Hib Vaccine, by Form USD Million (2015-2020)
  • Table 88. Europe Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 89. Europe Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 90. Europe Hib Vaccine, by End User USD Million (2015-2020)
  • Table 91. Germany Hib Vaccine, by Type USD Million (2015-2020)
  • Table 92. Germany Hib Vaccine, by Form USD Million (2015-2020)
  • Table 93. Germany Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 94. Germany Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 95. Germany Hib Vaccine, by End User USD Million (2015-2020)
  • Table 96. France Hib Vaccine, by Type USD Million (2015-2020)
  • Table 97. France Hib Vaccine, by Form USD Million (2015-2020)
  • Table 98. France Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 99. France Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 100. France Hib Vaccine, by End User USD Million (2015-2020)
  • Table 101. Italy Hib Vaccine, by Type USD Million (2015-2020)
  • Table 102. Italy Hib Vaccine, by Form USD Million (2015-2020)
  • Table 103. Italy Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 104. Italy Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 105. Italy Hib Vaccine, by End User USD Million (2015-2020)
  • Table 106. United Kingdom Hib Vaccine, by Type USD Million (2015-2020)
  • Table 107. United Kingdom Hib Vaccine, by Form USD Million (2015-2020)
  • Table 108. United Kingdom Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 109. United Kingdom Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 110. United Kingdom Hib Vaccine, by End User USD Million (2015-2020)
  • Table 111. Netherlands Hib Vaccine, by Type USD Million (2015-2020)
  • Table 112. Netherlands Hib Vaccine, by Form USD Million (2015-2020)
  • Table 113. Netherlands Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 114. Netherlands Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 115. Netherlands Hib Vaccine, by End User USD Million (2015-2020)
  • Table 116. Rest of Europe Hib Vaccine, by Type USD Million (2015-2020)
  • Table 117. Rest of Europe Hib Vaccine, by Form USD Million (2015-2020)
  • Table 118. Rest of Europe Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 119. Rest of Europe Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 120. Rest of Europe Hib Vaccine, by End User USD Million (2015-2020)
  • Table 121. MEA Hib Vaccine, by Country USD Million (2015-2020)
  • Table 122. MEA Hib Vaccine, by Type USD Million (2015-2020)
  • Table 123. MEA Hib Vaccine, by Form USD Million (2015-2020)
  • Table 124. MEA Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 125. MEA Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 126. MEA Hib Vaccine, by End User USD Million (2015-2020)
  • Table 127. Middle East Hib Vaccine, by Type USD Million (2015-2020)
  • Table 128. Middle East Hib Vaccine, by Form USD Million (2015-2020)
  • Table 129. Middle East Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 130. Middle East Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 131. Middle East Hib Vaccine, by End User USD Million (2015-2020)
  • Table 132. Africa Hib Vaccine, by Type USD Million (2015-2020)
  • Table 133. Africa Hib Vaccine, by Form USD Million (2015-2020)
  • Table 134. Africa Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 135. Africa Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 136. Africa Hib Vaccine, by End User USD Million (2015-2020)
  • Table 137. North America Hib Vaccine, by Country USD Million (2015-2020)
  • Table 138. North America Hib Vaccine, by Type USD Million (2015-2020)
  • Table 139. North America Hib Vaccine, by Form USD Million (2015-2020)
  • Table 140. North America Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 141. North America Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 142. North America Hib Vaccine, by End User USD Million (2015-2020)
  • Table 143. United States Hib Vaccine, by Type USD Million (2015-2020)
  • Table 144. United States Hib Vaccine, by Form USD Million (2015-2020)
  • Table 145. United States Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 146. United States Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 147. United States Hib Vaccine, by End User USD Million (2015-2020)
  • Table 148. Canada Hib Vaccine, by Type USD Million (2015-2020)
  • Table 149. Canada Hib Vaccine, by Form USD Million (2015-2020)
  • Table 150. Canada Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 151. Canada Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 152. Canada Hib Vaccine, by End User USD Million (2015-2020)
  • Table 153. Mexico Hib Vaccine, by Type USD Million (2015-2020)
  • Table 154. Mexico Hib Vaccine, by Form USD Million (2015-2020)
  • Table 155. Mexico Hib Vaccine, by Age Group USD Million (2015-2020)
  • Table 156. Mexico Hib Vaccine, by Infections USD Million (2015-2020)
  • Table 157. Mexico Hib Vaccine, by End User USD Million (2015-2020)
  • Table 158. Hib Vaccine Sales: by Type(K Tons)
  • Table 159. Hib Vaccine Sales Type 1-HIB Vaccine , by Region K Tons (2015-2020)
  • Table 160. Hib Vaccine Sales Type 2- DTaP-IPV , by Region K Tons (2015-2020)
  • Table 161. Hib Vaccine Sales: by Form(K Tons)
  • Table 162. Hib Vaccine Sales Liquid Monovalent HIB , by Region K Tons (2015-2020)
  • Table 163. Hib Vaccine Sales Liquid Combination HIB , by Region K Tons (2015-2020)
  • Table 164. Hib Vaccine Sales Lyophilized Monovalent HIB , by Region K Tons (2015-2020)
  • Table 165. Hib Vaccine Sales Lyophilized Combination HIB , by Region K Tons (2015-2020)
  • Table 166. Hib Vaccine Sales: by Age Group(K Tons)
  • Table 167. Hib Vaccine Sales Below 12-15 months ( Infants) , by Region K Tons (2015-2020)
  • Table 168. Hib Vaccine Sales 15 months -5 years , by Region K Tons (2015-2020)
  • Table 169. Hib Vaccine Sales 5 years and Above , by Region K Tons (2015-2020)
  • Table 170. Hib Vaccine Sales: by Infections(K Tons)
  • Table 171. Hib Vaccine Sales Meningitis (Inflammation Of The Lining Of The Brain And Spinal Cord) , by Region K Tons (2015-2020)
  • Table 172. Hib Vaccine Sales Bacteremia (Infection Of The Bloodstream) , by Region K Tons (2015-2020)
  • Table 173. Hib Vaccine Sales Pneumonia (Lung Infection) , by Region K Tons (2015-2020)
  • Table 174. Hib Vaccine Sales Epiglottitis (Throat Infection) , by Region K Tons (2015-2020)
  • Table 175. Hib Vaccine Sales: by End User(K Tons)
  • Table 176. Hib Vaccine Sales Hospital , by Region K Tons (2015-2020)
  • Table 177. Hib Vaccine Sales Research & Academic Laboratories , by Region K Tons (2015-2020)
  • Table 178. Hib Vaccine Sales Pharmaceutical & Biotechnology Companies , by Region K Tons (2015-2020)
  • Table 179. Hib Vaccine Sales Others , by Region K Tons (2015-2020)
  • Table 180. South America Hib Vaccine Sales, by Country K Tons (2015-2020)
  • Table 181. South America Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 182. South America Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 183. South America Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 184. South America Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 185. South America Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 186. Brazil Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 187. Brazil Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 188. Brazil Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 189. Brazil Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 190. Brazil Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 191. Argentina Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 192. Argentina Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 193. Argentina Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 194. Argentina Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 195. Argentina Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 196. Rest of South America Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 197. Rest of South America Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 198. Rest of South America Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 199. Rest of South America Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 200. Rest of South America Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 201. Asia Pacific Hib Vaccine Sales, by Country K Tons (2015-2020)
  • Table 202. Asia Pacific Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 203. Asia Pacific Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 204. Asia Pacific Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 205. Asia Pacific Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 206. Asia Pacific Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 207. China Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 208. China Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 209. China Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 210. China Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 211. China Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 212. Japan Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 213. Japan Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 214. Japan Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 215. Japan Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 216. Japan Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 217. India Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 218. India Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 219. India Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 220. India Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 221. India Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 222. South Korea Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 223. South Korea Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 224. South Korea Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 225. South Korea Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 226. South Korea Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 227. Taiwan Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 228. Taiwan Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 229. Taiwan Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 230. Taiwan Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 231. Taiwan Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 232. Australia Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 233. Australia Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 234. Australia Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 235. Australia Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 236. Australia Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 237. Rest of Asia-Pacific Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 238. Rest of Asia-Pacific Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 239. Rest of Asia-Pacific Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 240. Rest of Asia-Pacific Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 241. Rest of Asia-Pacific Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 242. Europe Hib Vaccine Sales, by Country K Tons (2015-2020)
  • Table 243. Europe Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 244. Europe Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 245. Europe Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 246. Europe Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 247. Europe Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 248. Germany Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 249. Germany Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 250. Germany Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 251. Germany Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 252. Germany Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 253. France Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 254. France Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 255. France Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 256. France Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 257. France Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 258. Italy Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 259. Italy Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 260. Italy Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 261. Italy Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 262. Italy Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 263. United Kingdom Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 264. United Kingdom Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 265. United Kingdom Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 266. United Kingdom Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 267. United Kingdom Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 268. Netherlands Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 269. Netherlands Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 270. Netherlands Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 271. Netherlands Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 272. Netherlands Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 273. Rest of Europe Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 274. Rest of Europe Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 275. Rest of Europe Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 276. Rest of Europe Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 277. Rest of Europe Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 278. MEA Hib Vaccine Sales, by Country K Tons (2015-2020)
  • Table 279. MEA Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 280. MEA Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 281. MEA Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 282. MEA Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 283. MEA Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 284. Middle East Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 285. Middle East Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 286. Middle East Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 287. Middle East Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 288. Middle East Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 289. Africa Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 290. Africa Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 291. Africa Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 292. Africa Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 293. Africa Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 294. North America Hib Vaccine Sales, by Country K Tons (2015-2020)
  • Table 295. North America Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 296. North America Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 297. North America Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 298. North America Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 299. North America Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 300. United States Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 301. United States Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 302. United States Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 303. United States Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 304. United States Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 305. Canada Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 306. Canada Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 307. Canada Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 308. Canada Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 309. Canada Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 310. Mexico Hib Vaccine Sales, by Type K Tons (2015-2020)
  • Table 311. Mexico Hib Vaccine Sales, by Form K Tons (2015-2020)
  • Table 312. Mexico Hib Vaccine Sales, by Age Group K Tons (2015-2020)
  • Table 313. Mexico Hib Vaccine Sales, by Infections K Tons (2015-2020)
  • Table 314. Mexico Hib Vaccine Sales, by End User K Tons (2015-2020)
  • Table 315. Hib Vaccine: by Type(USD/Units)
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Hib Vaccine: by Type(USD Million)
  • Table 327. Hib Vaccine Type 1-HIB Vaccine , by Region USD Million (2021-2026)
  • Table 328. Hib Vaccine Type 2- DTaP-IPV , by Region USD Million (2021-2026)
  • Table 329. Hib Vaccine: by Form(USD Million)
  • Table 330. Hib Vaccine Liquid Monovalent HIB , by Region USD Million (2021-2026)
  • Table 331. Hib Vaccine Liquid Combination HIB , by Region USD Million (2021-2026)
  • Table 332. Hib Vaccine Lyophilized Monovalent HIB , by Region USD Million (2021-2026)
  • Table 333. Hib Vaccine Lyophilized Combination HIB , by Region USD Million (2021-2026)
  • Table 334. Hib Vaccine: by Age Group(USD Million)
  • Table 335. Hib Vaccine Below 12-15 months ( Infants) , by Region USD Million (2021-2026)
  • Table 336. Hib Vaccine 15 months -5 years , by Region USD Million (2021-2026)
  • Table 337. Hib Vaccine 5 years and Above , by Region USD Million (2021-2026)
  • Table 338. Hib Vaccine: by Infections(USD Million)
  • Table 339. Hib Vaccine Meningitis (Inflammation Of The Lining Of The Brain And Spinal Cord) , by Region USD Million (2021-2026)
  • Table 340. Hib Vaccine Bacteremia (Infection Of The Bloodstream) , by Region USD Million (2021-2026)
  • Table 341. Hib Vaccine Pneumonia (Lung Infection) , by Region USD Million (2021-2026)
  • Table 342. Hib Vaccine Epiglottitis (Throat Infection) , by Region USD Million (2021-2026)
  • Table 343. Hib Vaccine: by End User(USD Million)
  • Table 344. Hib Vaccine Hospital , by Region USD Million (2021-2026)
  • Table 345. Hib Vaccine Research & Academic Laboratories , by Region USD Million (2021-2026)
  • Table 346. Hib Vaccine Pharmaceutical & Biotechnology Companies , by Region USD Million (2021-2026)
  • Table 347. Hib Vaccine Others , by Region USD Million (2021-2026)
  • Table 348. South America Hib Vaccine, by Country USD Million (2021-2026)
  • Table 349. South America Hib Vaccine, by Type USD Million (2021-2026)
  • Table 350. South America Hib Vaccine, by Form USD Million (2021-2026)
  • Table 351. South America Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 352. South America Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 353. South America Hib Vaccine, by End User USD Million (2021-2026)
  • Table 354. Brazil Hib Vaccine, by Type USD Million (2021-2026)
  • Table 355. Brazil Hib Vaccine, by Form USD Million (2021-2026)
  • Table 356. Brazil Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 357. Brazil Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 358. Brazil Hib Vaccine, by End User USD Million (2021-2026)
  • Table 359. Argentina Hib Vaccine, by Type USD Million (2021-2026)
  • Table 360. Argentina Hib Vaccine, by Form USD Million (2021-2026)
  • Table 361. Argentina Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 362. Argentina Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 363. Argentina Hib Vaccine, by End User USD Million (2021-2026)
  • Table 364. Rest of South America Hib Vaccine, by Type USD Million (2021-2026)
  • Table 365. Rest of South America Hib Vaccine, by Form USD Million (2021-2026)
  • Table 366. Rest of South America Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 367. Rest of South America Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 368. Rest of South America Hib Vaccine, by End User USD Million (2021-2026)
  • Table 369. Asia Pacific Hib Vaccine, by Country USD Million (2021-2026)
  • Table 370. Asia Pacific Hib Vaccine, by Type USD Million (2021-2026)
  • Table 371. Asia Pacific Hib Vaccine, by Form USD Million (2021-2026)
  • Table 372. Asia Pacific Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 373. Asia Pacific Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 374. Asia Pacific Hib Vaccine, by End User USD Million (2021-2026)
  • Table 375. China Hib Vaccine, by Type USD Million (2021-2026)
  • Table 376. China Hib Vaccine, by Form USD Million (2021-2026)
  • Table 377. China Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 378. China Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 379. China Hib Vaccine, by End User USD Million (2021-2026)
  • Table 380. Japan Hib Vaccine, by Type USD Million (2021-2026)
  • Table 381. Japan Hib Vaccine, by Form USD Million (2021-2026)
  • Table 382. Japan Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 383. Japan Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 384. Japan Hib Vaccine, by End User USD Million (2021-2026)
  • Table 385. India Hib Vaccine, by Type USD Million (2021-2026)
  • Table 386. India Hib Vaccine, by Form USD Million (2021-2026)
  • Table 387. India Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 388. India Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 389. India Hib Vaccine, by End User USD Million (2021-2026)
  • Table 390. South Korea Hib Vaccine, by Type USD Million (2021-2026)
  • Table 391. South Korea Hib Vaccine, by Form USD Million (2021-2026)
  • Table 392. South Korea Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 393. South Korea Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 394. South Korea Hib Vaccine, by End User USD Million (2021-2026)
  • Table 395. Taiwan Hib Vaccine, by Type USD Million (2021-2026)
  • Table 396. Taiwan Hib Vaccine, by Form USD Million (2021-2026)
  • Table 397. Taiwan Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 398. Taiwan Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 399. Taiwan Hib Vaccine, by End User USD Million (2021-2026)
  • Table 400. Australia Hib Vaccine, by Type USD Million (2021-2026)
  • Table 401. Australia Hib Vaccine, by Form USD Million (2021-2026)
  • Table 402. Australia Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 403. Australia Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 404. Australia Hib Vaccine, by End User USD Million (2021-2026)
  • Table 405. Rest of Asia-Pacific Hib Vaccine, by Type USD Million (2021-2026)
  • Table 406. Rest of Asia-Pacific Hib Vaccine, by Form USD Million (2021-2026)
  • Table 407. Rest of Asia-Pacific Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 408. Rest of Asia-Pacific Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 409. Rest of Asia-Pacific Hib Vaccine, by End User USD Million (2021-2026)
  • Table 410. Europe Hib Vaccine, by Country USD Million (2021-2026)
  • Table 411. Europe Hib Vaccine, by Type USD Million (2021-2026)
  • Table 412. Europe Hib Vaccine, by Form USD Million (2021-2026)
  • Table 413. Europe Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 414. Europe Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 415. Europe Hib Vaccine, by End User USD Million (2021-2026)
  • Table 416. Germany Hib Vaccine, by Type USD Million (2021-2026)
  • Table 417. Germany Hib Vaccine, by Form USD Million (2021-2026)
  • Table 418. Germany Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 419. Germany Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 420. Germany Hib Vaccine, by End User USD Million (2021-2026)
  • Table 421. France Hib Vaccine, by Type USD Million (2021-2026)
  • Table 422. France Hib Vaccine, by Form USD Million (2021-2026)
  • Table 423. France Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 424. France Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 425. France Hib Vaccine, by End User USD Million (2021-2026)
  • Table 426. Italy Hib Vaccine, by Type USD Million (2021-2026)
  • Table 427. Italy Hib Vaccine, by Form USD Million (2021-2026)
  • Table 428. Italy Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 429. Italy Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 430. Italy Hib Vaccine, by End User USD Million (2021-2026)
  • Table 431. United Kingdom Hib Vaccine, by Type USD Million (2021-2026)
  • Table 432. United Kingdom Hib Vaccine, by Form USD Million (2021-2026)
  • Table 433. United Kingdom Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 434. United Kingdom Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 435. United Kingdom Hib Vaccine, by End User USD Million (2021-2026)
  • Table 436. Netherlands Hib Vaccine, by Type USD Million (2021-2026)
  • Table 437. Netherlands Hib Vaccine, by Form USD Million (2021-2026)
  • Table 438. Netherlands Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 439. Netherlands Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 440. Netherlands Hib Vaccine, by End User USD Million (2021-2026)
  • Table 441. Rest of Europe Hib Vaccine, by Type USD Million (2021-2026)
  • Table 442. Rest of Europe Hib Vaccine, by Form USD Million (2021-2026)
  • Table 443. Rest of Europe Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 444. Rest of Europe Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 445. Rest of Europe Hib Vaccine, by End User USD Million (2021-2026)
  • Table 446. MEA Hib Vaccine, by Country USD Million (2021-2026)
  • Table 447. MEA Hib Vaccine, by Type USD Million (2021-2026)
  • Table 448. MEA Hib Vaccine, by Form USD Million (2021-2026)
  • Table 449. MEA Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 450. MEA Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 451. MEA Hib Vaccine, by End User USD Million (2021-2026)
  • Table 452. Middle East Hib Vaccine, by Type USD Million (2021-2026)
  • Table 453. Middle East Hib Vaccine, by Form USD Million (2021-2026)
  • Table 454. Middle East Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 455. Middle East Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 456. Middle East Hib Vaccine, by End User USD Million (2021-2026)
  • Table 457. Africa Hib Vaccine, by Type USD Million (2021-2026)
  • Table 458. Africa Hib Vaccine, by Form USD Million (2021-2026)
  • Table 459. Africa Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 460. Africa Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 461. Africa Hib Vaccine, by End User USD Million (2021-2026)
  • Table 462. North America Hib Vaccine, by Country USD Million (2021-2026)
  • Table 463. North America Hib Vaccine, by Type USD Million (2021-2026)
  • Table 464. North America Hib Vaccine, by Form USD Million (2021-2026)
  • Table 465. North America Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 466. North America Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 467. North America Hib Vaccine, by End User USD Million (2021-2026)
  • Table 468. United States Hib Vaccine, by Type USD Million (2021-2026)
  • Table 469. United States Hib Vaccine, by Form USD Million (2021-2026)
  • Table 470. United States Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 471. United States Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 472. United States Hib Vaccine, by End User USD Million (2021-2026)
  • Table 473. Canada Hib Vaccine, by Type USD Million (2021-2026)
  • Table 474. Canada Hib Vaccine, by Form USD Million (2021-2026)
  • Table 475. Canada Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 476. Canada Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 477. Canada Hib Vaccine, by End User USD Million (2021-2026)
  • Table 478. Mexico Hib Vaccine, by Type USD Million (2021-2026)
  • Table 479. Mexico Hib Vaccine, by Form USD Million (2021-2026)
  • Table 480. Mexico Hib Vaccine, by Age Group USD Million (2021-2026)
  • Table 481. Mexico Hib Vaccine, by Infections USD Million (2021-2026)
  • Table 482. Mexico Hib Vaccine, by End User USD Million (2021-2026)
  • Table 483. Hib Vaccine Sales: by Type(K Tons)
  • Table 484. Hib Vaccine Sales Type 1-HIB Vaccine , by Region K Tons (2021-2026)
  • Table 485. Hib Vaccine Sales Type 2- DTaP-IPV , by Region K Tons (2021-2026)
  • Table 486. Hib Vaccine Sales: by Form(K Tons)
  • Table 487. Hib Vaccine Sales Liquid Monovalent HIB , by Region K Tons (2021-2026)
  • Table 488. Hib Vaccine Sales Liquid Combination HIB , by Region K Tons (2021-2026)
  • Table 489. Hib Vaccine Sales Lyophilized Monovalent HIB , by Region K Tons (2021-2026)
  • Table 490. Hib Vaccine Sales Lyophilized Combination HIB , by Region K Tons (2021-2026)
  • Table 491. Hib Vaccine Sales: by Age Group(K Tons)
  • Table 492. Hib Vaccine Sales Below 12-15 months ( Infants) , by Region K Tons (2021-2026)
  • Table 493. Hib Vaccine Sales 15 months -5 years , by Region K Tons (2021-2026)
  • Table 494. Hib Vaccine Sales 5 years and Above , by Region K Tons (2021-2026)
  • Table 495. Hib Vaccine Sales: by Infections(K Tons)
  • Table 496. Hib Vaccine Sales Meningitis (Inflammation Of The Lining Of The Brain And Spinal Cord) , by Region K Tons (2021-2026)
  • Table 497. Hib Vaccine Sales Bacteremia (Infection Of The Bloodstream) , by Region K Tons (2021-2026)
  • Table 498. Hib Vaccine Sales Pneumonia (Lung Infection) , by Region K Tons (2021-2026)
  • Table 499. Hib Vaccine Sales Epiglottitis (Throat Infection) , by Region K Tons (2021-2026)
  • Table 500. Hib Vaccine Sales: by End User(K Tons)
  • Table 501. Hib Vaccine Sales Hospital , by Region K Tons (2021-2026)
  • Table 502. Hib Vaccine Sales Research & Academic Laboratories , by Region K Tons (2021-2026)
  • Table 503. Hib Vaccine Sales Pharmaceutical & Biotechnology Companies , by Region K Tons (2021-2026)
  • Table 504. Hib Vaccine Sales Others , by Region K Tons (2021-2026)
  • Table 505. South America Hib Vaccine Sales, by Country K Tons (2021-2026)
  • Table 506. South America Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 507. South America Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 508. South America Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 509. South America Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 510. South America Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 511. Brazil Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 512. Brazil Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 513. Brazil Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 514. Brazil Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 515. Brazil Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 516. Argentina Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 517. Argentina Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 518. Argentina Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 519. Argentina Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 520. Argentina Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 521. Rest of South America Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 522. Rest of South America Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 523. Rest of South America Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 524. Rest of South America Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 525. Rest of South America Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 526. Asia Pacific Hib Vaccine Sales, by Country K Tons (2021-2026)
  • Table 527. Asia Pacific Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 528. Asia Pacific Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 529. Asia Pacific Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 530. Asia Pacific Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 531. Asia Pacific Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 532. China Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 533. China Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 534. China Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 535. China Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 536. China Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 537. Japan Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 538. Japan Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 539. Japan Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 540. Japan Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 541. Japan Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 542. India Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 543. India Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 544. India Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 545. India Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 546. India Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 547. South Korea Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 548. South Korea Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 549. South Korea Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 550. South Korea Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 551. South Korea Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 552. Taiwan Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 553. Taiwan Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 554. Taiwan Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 555. Taiwan Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 556. Taiwan Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 557. Australia Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 558. Australia Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 559. Australia Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 560. Australia Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 561. Australia Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 562. Rest of Asia-Pacific Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 563. Rest of Asia-Pacific Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 564. Rest of Asia-Pacific Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 565. Rest of Asia-Pacific Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 566. Rest of Asia-Pacific Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 567. Europe Hib Vaccine Sales, by Country K Tons (2021-2026)
  • Table 568. Europe Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 569. Europe Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 570. Europe Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 571. Europe Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 572. Europe Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 573. Germany Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 574. Germany Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 575. Germany Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 576. Germany Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 577. Germany Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 578. France Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 579. France Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 580. France Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 581. France Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 582. France Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 583. Italy Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 584. Italy Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 585. Italy Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 586. Italy Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 587. Italy Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 588. United Kingdom Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 589. United Kingdom Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 590. United Kingdom Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 591. United Kingdom Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 592. United Kingdom Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 593. Netherlands Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 594. Netherlands Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 595. Netherlands Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 596. Netherlands Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 597. Netherlands Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 598. Rest of Europe Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 599. Rest of Europe Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 600. Rest of Europe Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 601. Rest of Europe Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 602. Rest of Europe Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 603. MEA Hib Vaccine Sales, by Country K Tons (2021-2026)
  • Table 604. MEA Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 605. MEA Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 606. MEA Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 607. MEA Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 608. MEA Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 609. Middle East Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 610. Middle East Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 611. Middle East Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 612. Middle East Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 613. Middle East Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 614. Africa Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 615. Africa Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 616. Africa Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 617. Africa Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 618. Africa Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 619. North America Hib Vaccine Sales, by Country K Tons (2021-2026)
  • Table 620. North America Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 621. North America Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 622. North America Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 623. North America Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 624. North America Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 625. United States Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 626. United States Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 627. United States Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 628. United States Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 629. United States Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 630. Canada Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 631. Canada Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 632. Canada Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 633. Canada Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 634. Canada Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 635. Mexico Hib Vaccine Sales, by Type K Tons (2021-2026)
  • Table 636. Mexico Hib Vaccine Sales, by Form K Tons (2021-2026)
  • Table 637. Mexico Hib Vaccine Sales, by Age Group K Tons (2021-2026)
  • Table 638. Mexico Hib Vaccine Sales, by Infections K Tons (2021-2026)
  • Table 639. Mexico Hib Vaccine Sales, by End User K Tons (2021-2026)
  • Table 640. Hib Vaccine: by Type(USD/Units)
  • Table 641. Research Programs/Design for This Report
  • Table 642. Key Data Information from Secondary Sources
  • Table 643. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hib Vaccine: by Type USD Million (2015-2020)
  • Figure 5. Global Hib Vaccine: by Form USD Million (2015-2020)
  • Figure 6. Global Hib Vaccine: by Age Group USD Million (2015-2020)
  • Figure 7. Global Hib Vaccine: by Infections USD Million (2015-2020)
  • Figure 8. Global Hib Vaccine: by End User USD Million (2015-2020)
  • Figure 9. South America Hib Vaccine Share (%), by Country
  • Figure 10. Asia Pacific Hib Vaccine Share (%), by Country
  • Figure 11. Europe Hib Vaccine Share (%), by Country
  • Figure 12. MEA Hib Vaccine Share (%), by Country
  • Figure 13. North America Hib Vaccine Share (%), by Country
  • Figure 14. Global Hib Vaccine: by Type K Tons (2015-2020)
  • Figure 15. Global Hib Vaccine: by Form K Tons (2015-2020)
  • Figure 16. Global Hib Vaccine: by Age Group K Tons (2015-2020)
  • Figure 17. Global Hib Vaccine: by Infections K Tons (2015-2020)
  • Figure 18. Global Hib Vaccine: by End User K Tons (2015-2020)
  • Figure 19. South America Hib Vaccine Share (%), by Country
  • Figure 20. Asia Pacific Hib Vaccine Share (%), by Country
  • Figure 21. Europe Hib Vaccine Share (%), by Country
  • Figure 22. MEA Hib Vaccine Share (%), by Country
  • Figure 23. North America Hib Vaccine Share (%), by Country
  • Figure 24. Global Hib Vaccine: by Type USD/Units (2015-2020)
  • Figure 25. Global Hib Vaccine share by Players 2020 (%)
  • Figure 26. Global Hib Vaccine share by Players (Top 3) 2020(%)
  • Figure 27. Global Hib Vaccine share by Players (Top 5) 2020(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 31. SINOPHARM (China) Revenue, Net Income and Gross profit
  • Figure 32. SINOPHARM (China) Revenue: by Geography 2020
  • Figure 33. Weldon Biotech, Inc. (India) Revenue, Net Income and Gross profit
  • Figure 34. Weldon Biotech, Inc. (India) Revenue: by Geography 2020
  • Figure 35. McKesson Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 36. McKesson Corporation (United States) Revenue: by Geography 2020
  • Figure 37. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 39. Merck Sharp & Dohme Corp (United States) Revenue, Net Income and Gross profit
  • Figure 40. Merck Sharp & Dohme Corp (United States) Revenue: by Geography 2020
  • Figure 41. Sanofi Pasteur (Canada) Revenue, Net Income and Gross profit
  • Figure 42. Sanofi Pasteur (Canada) Revenue: by Geography 2020
  • Figure 43. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 45. Takeda Pharmaceuticals Company Ltd.(Japan) Revenue, Net Income and Gross profit
  • Figure 46. Takeda Pharmaceuticals Company Ltd.(Japan) Revenue: by Geography 2020
  • Figure 47. Walvax Biotechnology Co. Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 48. Walvax Biotechnology Co. Ltd. (China) Revenue: by Geography 2020
  • Figure 49. Global Hib Vaccine: by Type USD Million (2021-2026)
  • Figure 50. Global Hib Vaccine: by Form USD Million (2021-2026)
  • Figure 51. Global Hib Vaccine: by Age Group USD Million (2021-2026)
  • Figure 52. Global Hib Vaccine: by Infections USD Million (2021-2026)
  • Figure 53. Global Hib Vaccine: by End User USD Million (2021-2026)
  • Figure 54. South America Hib Vaccine Share (%), by Country
  • Figure 55. Asia Pacific Hib Vaccine Share (%), by Country
  • Figure 56. Europe Hib Vaccine Share (%), by Country
  • Figure 57. MEA Hib Vaccine Share (%), by Country
  • Figure 58. North America Hib Vaccine Share (%), by Country
  • Figure 59. Global Hib Vaccine: by Type K Tons (2021-2026)
  • Figure 60. Global Hib Vaccine: by Form K Tons (2021-2026)
  • Figure 61. Global Hib Vaccine: by Age Group K Tons (2021-2026)
  • Figure 62. Global Hib Vaccine: by Infections K Tons (2021-2026)
  • Figure 63. Global Hib Vaccine: by End User K Tons (2021-2026)
  • Figure 64. South America Hib Vaccine Share (%), by Country
  • Figure 65. Asia Pacific Hib Vaccine Share (%), by Country
  • Figure 66. Europe Hib Vaccine Share (%), by Country
  • Figure 67. MEA Hib Vaccine Share (%), by Country
  • Figure 68. North America Hib Vaccine Share (%), by Country
  • Figure 69. Global Hib Vaccine: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • SINOPHARM (China)
  • Weldon Biotech, Inc. (India)
  • McKesson Corporation (United States)
  • Novartis (Switzerland)
  • Merck Sharp & Dohme Corp (United States)
  • Sanofi Pasteur (Canada)
  • GlaxoSmithKline (United Kingdom)
  • Takeda Pharmaceuticals Company Ltd.(Japan)
  • Walvax Biotechnology Co. Ltd. (China)
Additional players considered in the study are as follows:
Lanzhou Institute of Biological Products Co., Ltd(China) , Bharat Biotech(India) , Serum Institute of India Pvt. Ltd (India) , Seqirus (United Kingdom)
Select User Access Type

Key Highlights of Report


Feb 2021 241 Pages 74 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hib Vaccine Quantitative research analysis
Global Hib Vaccine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AstraZeneca (United Kingdom), SINOPHARM (China), Weldon Biotech, Inc. (India), McKesson Corporation (United States), Novartis (Switzerland), Merck Sharp & Dohme Corp (United States), Sanofi Pasteur (Canada), GlaxoSmithKline (United Kingdom), Takeda Pharmaceuticals Company Ltd.(Japan) and Walvax Biotechnology Co. Ltd. (China) etc.
Analysts at AMA estimates Hib Vaccine Market to reach USDXXX by 2026.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Hib Vaccine Report?

Have a Query? Click Here

Other Related Reports

Breast Cancer Predictive Genetic Testing Comprehensive Study by Type (High Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes), Application (Hospitals, Clinic Center, Pharmaceuticals,...
$ 3500
Adenovirus Vaccine Comprehensive Study by Type (Type 4 Vaccine, Type 7 Vaccine), Application (Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others) Players and Region - ...
$ 3500
Allergic Rhinitis Drugs Comprehensive Study by Type (Corticosteroids, Antihistamines, Vasoconstrictors, Pratropium Bromide, Others (Leukotrienes, Cromoglycate)), Application (Non-Allergic Rhinitis, M...
$ 3650
Dental Drugs Comprehensive Study by Type (Analgesic, Anesthetics, Antibiotics, Antifungals, Antiseptics, Fluorides, Benzodiazepines, Saliva Substitutes), Mode of Administration (Injectable, Oral, Spr...
$ 3450
Clarityne Comprehensive Study by Type (Loratadine Tablet, Loratadine Capsule, Loratadine Syrup), Application (Adult Drug, Pediatric Drug), Sales Channel (Hospitals, Drug Store, Specialty Pharmacy, E-...
$ 3500
General Anesthesia Drugs Comprehensive Study by Type (Propofol, Dexmedetomidine, Sevoflurane, Desflurane, Midazolam, Others), Application (Inhalational Anesthetics, Intravenous Anesthetics), Distribu...
$ 3650